Download
hiv iii prevention of hiv infection n.
Skip this Video
Loading SlideShow in 5 Seconds..
HIV III- Prevention of HIV infection PowerPoint Presentation
Download Presentation
HIV III- Prevention of HIV infection

HIV III- Prevention of HIV infection

307 Views Download Presentation
Download Presentation

HIV III- Prevention of HIV infection

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. HIV III-Prevention of HIV infection Allison Liddell, MD Monday, January 24th, 2005

  2. HIV Curriculum • HIV I-Diagnosis and HAART • HIV II-Complications of HIV/AIDS • HIV III-Prevention of HIV infection

  3. Date of first published case? June 5, 1981 Where? MMWR five cases ofPCP among previously healthy young men in What city? Los Angeles. All of the men were described as "homosexuals"; two had died. Who wrote it? Local clinicians and the Epidemic Intelligence Service (EIS) Officer stationed at the Los Angeles County Department of Public Health editorial note stated that the histories suggested a "cellular-immune dysfunction related to a common exposure" and a "disease acquired through sexual contact." HIV history

  4. HIV history • CDC's investigation drug unit, the sole distributor of pentamidine, the therapy for PCP, began to receive requests for the drug from physicians also to treat young men • June 1981, CDC developed an investigative team • Within 18 months, epidemiologists conducted studies and prepared MMWR reports that identified all of the major risks factors for acquired immnodeficiency syndrome (AIDS).

  5. HIV Prevention • CDC initiative: Advancing HIV Prevention:New Strategies for a Changing Epidemic • reducing barriers to early diagnosis • increasing access to quality medical care, treatment • ongoing prevention services • emphasizes the use of proven public health approaches to • appropriate routine screening • identification of new cases • partner counseling and referral • increased availability of sustained treatment • prevention services for the infected

  6. must be used correctly and consistently Latex condoms are highly effective in preventing transmission of HIV. Well documented. reduce the risk of other STDs associated with a lower rate of cervical cancer, an HPV-associated disease. condoms lubricated with spermicides are no more effective epidemiologic studies of STDs, other than HIV, are characterized by methodological limitations inconclusiveness of epidemiologic data about condom effectiveness for other STDs indicates that more research is needed--not that latex condoms do not work Barrier Methods. Do they work?

  7. Epidemiologic studies that are conducted in real-life settings, where one partner is infected with HIV and the other partner is not, demonstrate conclusively that the consistent use of latex condoms provides a high degree of protection.

  8. Vertical Transmission • 91% of all AIDS cases reported among U.S. children • February 1994 PACTG Protocol 076 documented that ZDV chemoprophylaxis could reduce perinatal HIV-1 transmission by nearly 70% • transmission rates can be reduced to less than 2% (Cooper 2002) compared with approximately 25% when no interventions are given (Connor 1994).

  9. Results of ACTG 076 30 66% reduction in risk for transmission (P = <0.001) Efficacy observed in all subgroups 20 22.6% Transmission Rate (%) 10 7.6% Placebo ZDV Group

  10. Vertical Transmission • perinatally acquired AIDS cases declined 90% in the US during 1992-2000 (912 cases to 90 cases) CDC unpublished data • Lifetime treatment cost for perinatally infected infants $51.8-$68.5 million • assumes 280-370 perinatal infections per year • lifetime cost of $185,000 per infant (Mrus 2004). • 90% of mothers were voluntarily tested for HIV before birth for 1999-2001. • 79% of HIV-infected women and infants received antiretroviral therapy prenatally • 77% at labor/delivery • 92% neonatally • 8% of the HIV-infected pregnant women identified had not received prenatal care (CDC 2004). • Another study concluded that approximately 14% of HIV-infected pregnant women do not receive any prenatal care

  11. pregnancy is not a reason to defer standard therapy unique considerations need to alter dosage as a result of physiologic changes associated with pregnancy potential for adverse short- or long-term effects on the fetus and newborn conflicting data on asso. between HAART and preterm delivery to prevent perinatal transmission, ZDV chemoprophylaxis should be incorporated into the antiretroviral regimen AZT alone may be considered for prophylaxis of perinatal transmission in pregnant women with HIV RNA <1,000 copies/mL HIV in pregnancy

  12. NRTI Abacavir ABC Didanosine DDI Emtricitabine FTC Lamivudine 3TC Stavudine D4T Zidovudine ZDV Zalcitabine DDC Tenofovir TDF NNRTI Delavirdine DLV Efavirenz EFV Nevirapine NVP PI Amprenavir APV Atazanavir ATV Fosamprenavir FPV Indinavir IDV Lopinavir LPV Nelfinavir NFV Ritonavir RTV Saquinavir SQV soft gel SGC hard gel HGC Fusion Inhibitor Enfuvirtide T-20 Current Antiretroviral Medications

  13. Nevirapine Increases in hepatic transaminase levels (ALT and AST) associated with rash or systemic symptoms may be observed during the first 18 weeks risk increases with CD4+ cell count nevirapine-associated liver failure or hepatic mortality 0.04-0.40% severe rash has 5.5 to 7.3 times more common in women (overall 2%) Woman >250 12 fold RR not reported for single doses given to mother and child for prevention of perinatal HIV infection deaths due to hepatic failure have been reported in HIV-infected pregnant women frequent monitoring of clinical symptoms and LFTs use with caution in pregnant antiretroviral-naïve women with higher CD4 label now recommends against starting nevirapine treatment in women with CD4>250 cells/mm3 unless benefits clearly outweigh risks (1/19/05) HAART in pregnancy

  14. Protease inhibitors Hyperglycemia Nelfinavir preferred Newer ones no data Efavirenz Significant malformations (anencephaly, anophthalmia, cleft palate) in 3/20 (15%) infants born to monkeys receiving efavirenz during first trimester 3 case reports of neural tube defects in humans w/first trimester exposure NRTI’s Lots of data mitochondrial dysfunction affinity for mitochondrial gamma DNA polymerase highest for ddC>ddI>stavudine >ZDV>3TC>abacavir >tenofovir generally has resolved with discontinuation possible genetic factor Tenofovir Insufficient data HAART in pregnancy

  15. Prenatal screening • In 2003, CDC recommended that HIV testing be included in the standard battery of prenatal tests and procedures, with notification to pregnant women that the test would be performed and could be declined (CDC 2003b). • similar to recommendations by the Institute of Medicine (IOM 1999) • American College of Obstetricians and Gynecologists (AAP, ACOG 1999). • American Academy of Pediatrics (AAP, ACOG 1999).

  16. Key Strategies • Universal, routine HIV screening of all pregnant women • Universal, routine retesting in the third trimester if: • HIV seroprevalence (>0.5%) or • high risk • history of sexually transmitted diseases (STDs) • sex for money or drugs • multiple sex partners during pregnancy • illicit drugs • sex partner(s) known to be HIV+ or at high risk, • signs and symptoms of seroconversion) Universal, routine rapid HIV testing among untested women on arrival • rapid HIV testing of newborns whose mothers were not previously screened for HIV • Appropriate treatment for pregnant women determined to be HIV-infected and prophylaxis for their infants.

  17. Prevention of transmission • 3-part regimen • oral ZDV initiated at 14-34 weeks' gestation • intravenous ZDV during labor • oral ZDV to infant for 6 weeks after delivery • No breastfeeding if safe alternatives available

  18. HIV prevention in the workplace • Key is good policies and procedures and education, education, education NIOSH

  19. Airborne/Droplet Tuberculosis Influenza, RSV pertussis SARS Feces Hep A Contact Scabies Varicella RSV GAS Transmission of Infection to HCW’s • Blood and body fluids • Hep B • Hep C • HIV

  20. Question • Assuming a nonimmune HCW and no treatment, which virus is most likely to result in transmission after a percutaneous exposure? • Hep A • Hep B • Hep C • HIV • Hep B (2-40%) > Hep C (3-10%) > HIV (0.1-0.5%) • But, HCW’s should be protected against B • We can prevent and treat HIV • We can treat C

  21. Nurses most common Physicians, others underreport Risk factors Hollow-bore device Visible blood Depth of injury Patient factors Prevention Safety devices Training procedures no recapping proper disposal Bloodborne pathogen exposure

  22. Recommendations and Reports January 21, 2005 / 54(RR02);1-20 Antiretroviral Postexposure Prophylaxis After Sexual, Injection-Drug Use, or Other Nonoccupational Exposure to HIV in the United States Recommendations from the U.S. Department of Health and Human Services.htm Link to Recommendations

  23. Voluntary sex Sharing needles Accidental injury Blood transfusion Sexual assault 13% of adult women report having been raped (60% before age 18) 5% more than once 5% of reported rapes in ER involved men assaulting men National Crime Victimization Survey 1999 In >12yo, 11.6 % men only 3 documented cases of HIV infection resulting from rape Nonoccupational Exposures MMWRJanuary 21, 2005 / 54(RR02);1-20

  24. Study of men incarcerated in Rhode Island 1% of convicted rapists were HIV infected (3% of all prisoners and 0.3% of the general males) multiple characteristics increase risk for HIV transmission. Study of 1,076 cases: 20% multiple assailants 39% strangers 83% of females were vaginally penetrated 17% sodomized. Genital in 53% sperm or semen was detected in 48% 40% of assaulted women (70% of nulliparas) had vaginal lacerations, compared with 5% after consensual sex sexual assault survivors often decline nPEP many who do take it do not complete the 28-day course. In Vancouver 71/258 assault survivors accepted the 5-day starter pack of nPEP 29 returned for additional doses 8 completed 4 weeks. Those with the highest risk for HIV exposure more likely to begin and complete nPEP. Transmission via sexual assault

  25. Nonoccupational Exposure (nPEP) • Known HIV + • <72 hours after nonoccupational exposure to blood, genital secretions, or other potentially infectious body fluids of a person • substantial risk for transmission • 28-day course of (HAART) • initiated ASAP after exposure. • consider nPEP for serious risk for transmission, even if >72 hours if benefit>risk • Frequent, voluntary exposure-no HAART • Unknown HIV status • substantial risk for transmission if the source were HIV infected • no recommendations are made for the use of nPEP • evaluate risks and benefits of nPEP on a case-by-case basis. • no substantial risk for HIV transmission or who seek care >72 hours-no HAART • Risk-reduction counseling and indicated intervention services should be provided to reduce the risk for recurrent exposures. MMWRJanuary 21, 2005 / 54(RR02);1-20

  26. Concerns about nPEP • increases in risk behavior-not supported by data • Toxicity • Selection of resistance • Cost effectiveness MMWRJanuary 21, 2005 / 54(RR02);1-20

  27. PEP registry 492 health-care workers. 76% reported certain symptoms (i.e., nausea [57%] and fatigue or malaise [38%]). 8% had laboratory abnormalities. All resolved promptly at the end of antiretroviral treatment. Six (1.3%) reported severe adverse events. Four stopped PEP because of side effects. Of 68 workers who stopped taking PEP despite exposure to a source person known to be HIV-positive, 29 (43%) stopped because of side effects. Toxicity MMWRJanuary 21, 2005 / 54(RR02);1-20

  28. U.S. nPEP surveillance registry, among. 107 exposures. initial regimen stopped or modified in 22%; 50% due to side effects. serious side effects have been reported (e.g., nephrolithiasis and hepatitis). Nevirapine 1997--2000. 22 severe ADRs for PEP or nPEP reported to FDA. 12 severe hepatotoxicity (one transplant), 14 severe skin reactions, 4 both. risk of nevirapine-containing regimen for occupational PEP outweighs benefits. nevirapine should not be used for nPEP. Toxicity MMWRJanuary 21, 2005 / 54(RR02);1-20

  29. Selection of Resistance • “probably rare” • PEP failures have been documented after at least one sexual and 21 occupational exposures • 3/4 AZT only • Only 4 3+ drugs • 1 had 3TC mutation, but source unknown • Consider resistance testing if patient does seroconvert MMWRJanuary 21, 2005 / 54(RR02);1-20

  30. US study cost-effective only with known HIV+ source or after unprotected receptive anal intercourse with a homosexual or bisexual man of unknown serostatus. French study nPEP cost-saving for unprotected receptive anal intercourse with known HIV + partner and for receptive anal intercourse with a homosexual or bisexual partner of unknown serostatus not cost-effective for penile-vaginal sex, insertive anal intercourse, or other exposures considered. British Columbia study (already doing nPEP) >50% did not fit criteria (e.g., for exposure to intact skin). use of nonindicated nPEP doubled the cost per HIV infection prevented ($530,000 vs. $230,000) Even if nPEP is cost-effective for highest risk exposures, behavioral interventions more cost-effective. Emphasizes the importance of providing risk-avoidance and risk-reduction counseling to reduce the occurrence of future HIV exposures. Cost effectiveness MMWRJanuary 21, 2005 / 54(RR02);1-20

  31. Failure to report Cost to patient Harder to test source Barriers to nPEP

  32. Blood is key source Infected saliva very low risk Rapidly test and interview source (?viral load, HAART, prior resistance) If experts not immediately available, do not delay Facilitate adherence Frank, nonjudgemental counseling about risk behaviors Treatment for other blood borne or sexually transmitted infections Emergency contraception Referral for psychiatric services Evaluation of Exposure

  33. 35yo WM found HIV+ on insurance exam. Only symptom is occasional night sweats. Thrush on exam. CD4 260. Viral load 1550. Management? Begin treatment with a 3-drug regimen and start PCP prophylaxis. Question

  34. 25yo WM in ER for fever/cough x 2weeks. HIV+ in prison for 4+ years, now on parole. Decreased BS in right mid lung, sat 98% RA, RML infiltrate on CXR. You admit. Plan? Airborne isolation, rx for CAP and collect sputa Question

  35. 30 yo WM HIV+, no meds, 1 week HA, fever, anorexia, N/V. Thin, lethargic. Neck supple, neuro exam nonfocal. WBC 2.5, plts 150K LP OP 39cm, WBC 25, pro 65, glu 50. India ink +, crypto ag titer >1:8192. Plan? Begin antifungal therapy (Ampho + 5FC) and repeat the LP daily (normal opening pressure 10-20 cm) Controversial whether to start HAART Question

  36. 36yo WM HIV+ 10 years, no HAART in 5 yrs, to ER w/new onset seizures. 2 weeks memory loss, odd behavior. Confused, disoriented. MRI single ring-enhancing lesion left cerebral hemisphere arising in basal ganglia, with significant mass effect and midline shift. Start empiric pyrimethamine/sulfa (or clinda). No LP. Question Admit, steroids, CD4=17, toxo IgM neg, IgG+, CMV IgM neg, IgG+. Next step?

  37. 25yo BF HIV+ for 2 years, now in 8th week of pregnancy. Asympto, CD4>700, viral loads <1000. NO HAART ever. Plan? AZT only starting beginning of second trimester, then routine perinatal AZT. Question

  38. 38 yo LAM with chronic HIV admit w/pneumonia. Migrant worker from Mexico. Bilateral interstitial infiltrates, no HAART, no history of OIs. Hypoxic, intubated. Worsens on PCP rx, bronch shows long larvae. Dx? Strongyloides stercoralis Question